{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:47:19Z","timestamp":1789015639931,"version":"build-2803163510"},"reference-count":22,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The appropriate therapy for limited-stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is unclear. In contrast to classical Hodgkin lymphoma (CHL), chemotherapy is often omitted; however, it is unknown whether this impacts the risk of relapse. Herein, we compared the outcome of patients with limited-stage NLPHL treated in an era in which ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy was routinely incorporated into the primary therapy to an earlier era in which radiotherapy (RT) was used as a single modality. Using the British Columbia Cancer Agency Lymphoid Cancer Database, 88 patients with limited-stage NLPHL (stage 1A\/1B or 2A, nonbulky disease &lt; 10 cm) were identified. Treatment followed era-specific guidelines: before 1993, (n = 32) RT alone; and 1993 to present (n = 56), ABVD-like chemotherapy for 2 cycles followed by RT with the exception of 14 patients who received ABVD chemotherapy alone. Most patients were male (75%) with stage I disease (61%). In an era-to-era comparison, the 10-year time to progression (98% vs 76% P = .0074), progression-free survival (91% vs 65% P = .0024), and OS (93% vs 84%, P = .074) favored the ABVD treatment era compared with the RT alone era. Treating limited-stage NLPHL similarly to CHL may improve outcome compared with the use of radiation alone.<\/jats:p>","DOI":"10.1182\/blood-2011-07-365932","type":"journal-article","created":{"date-parts":[[2011,8,27]],"date-time":"2011-08-27T05:25:48Z","timestamp":1314422748000},"page":"4585-4590","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome"],"prefix":"10.1182","volume":"118","author":[{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Skinnider","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Pathology, British Columbia Cancer Agency, Vancouver, BC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Al-Mansour","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Pathology, British Columbia Cancer Agency, Vancouver, BC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111807261283600_B1","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma.","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue","author":"Poppema","year":"2008"},{"issue":"5","key":"2019111807261283600_B2","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"key":"2019111807261283600_B3","unstructured":"Hoppe\n              RT\n            \n            \n              Advani\n              RH\n            \n            \n              Ai\n              WZ\n            \n            \n          \n          NCCN Clinical practice guidelines in oncology: Hodgkin lymphoma.\n          National Comprehensive Cancer Network\n          Accessed June 2011\n          \n            www.nccn.org"},{"issue":"6","key":"2019111807261283600_B4","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0959-8049(96)00518-7","article-title":"Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone.","volume":"33","author":"Horwich","year":"1997","journal-title":"Eur J Cancer"},{"issue":"5","key":"2019111807261283600_B5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807261283600_B6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"key":"2019111807261283600_B7","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008","edition":"4th ed"},{"issue":"32","key":"2019111807261283600_B8","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807261283600_B9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807261283600_B10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"2019111807261283600_B11","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/annonc\/mdq063","article-title":"Lymphocyte-predominant Hodgkin lymphoma: clinical features and treatment outcomes from a 30-year experience.","volume":"21","author":"Jackson","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111807261283600_B12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807261283600_B13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.","volume":"26","author":"Nogova","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807261283600_B14","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","article-title":"Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"2019111807261283600_B15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/annonc\/mdq181","article-title":"Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"21","author":"Engert","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111807261283600_B16","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte: very favorable and favorable, lymphocyte-predominant Hodgkin disease.","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"issue":"7","key":"2019111807261283600_B17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111807261283600_B18","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807261283600_B19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma: experience from the European network group on pediatric Hodgkin lymphoma.","volume":"110","author":"Mauz-Korholz","year":"2007","journal-title":"Cancer"},{"key":"2019111807261283600_B20","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte predominant Hodgkin's disease: results of a phase II trial.","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"2019111807261283600_B21","doi-asserted-by":"crossref","first-page":"644a","DOI":"10.1182\/blood.V110.11.644.644","article-title":"Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) [abstract].","volume":"110","author":"Horning","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111807261283600_B22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/17\/4585\/1462781\/zh804311004585.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/17\/4585\/1462781\/zh804311004585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:34:20Z","timestamp":1574080460000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/17\/4585\/29022\/Treating-limitedstage-nodular-lymphocyte"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,27]]},"references-count":22,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2011,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-365932","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,27]]}}}